Histamine 2/3 receptor agonists alleviate perioperative neurocognitive disorders by inhibiting microglia activation through the PI3K/AKT/FoxO1 pathway in aged rats
Background Microglia, the principal sentinel immune cells of the central nervous system (CNS), play an extensively vital role in neuroinflammation and perioperative neurocognitive disorders (PND). Histamine, a potent mediator of inflammation, can both promote and prevent microglia-related neuroinflammation by activating different histamine receptors. Rat microglia express four histamine receptors (H1R, H2R, H3R, and H4R), among which the histamine 1 and 4 receptors can promote microglia activation, whereas the role and cellular mechanism of the histamine 2 and 3 receptors have not been elucidated. Therefore, we evaluated the effects and potential cellular mechanisms of histamine 2/3 receptors in microglia-mediated inflammation and PND. Methods This study investigated the role of histamine 2/3 receptors in microglia-induced inflammation and PND both in vivo and in vitro. In the in vivo experiments, rats were injected with histamine 2/3 receptor agonists in the right lateral ventricle and were then subjected to exploratory laparotomy. In the in vitro experiments, primary microglia were pretreated with histamine 2/3 receptor agonists before stimulation with lipopolysaccharide (LPS). Cognitive function, microglia activation, proinflammatory cytokine production, NF-κb expression, M1/M2 phenotypes, cell migration, and Toll-like receptor-4 (TLR4) expression were assessed. Results In our study, the histamine 2/3 receptor agonists inhibited exploratory laparotomy- or LPS-induced cognitive decline, microglia activation, proinflammatory cytokine production, NF-κb expression, M1/M2 phenotype transformation, cell migration, and TLR4 expression through the PI3K/AKT/FoxO1 pathway. Conclusion Based on our findings, we conclude that histamine 2/3 receptors ameliorate PND by inhibiting microglia activation through the PI3K/AKT/FoxO1 pathway. Our results highlight histamine 2/3 receptors as potential therapeutic targets to treat neurological conditions associated with PND..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of neuroinflammation - 17(2020), 1 vom: 22. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yi-Nan [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
FoxO1 |
|---|
| doi: |
10.1186/s12974-020-01886-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR040427013 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR040427013 | ||
| 003 | DE-627 | ||
| 005 | 20230520001410.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12974-020-01886-2 |2 doi | |
| 035 | |a (DE-627)SPR040427013 | ||
| 035 | |a (SPR)s12974-020-01886-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Chen, Yi-Nan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Histamine 2/3 receptor agonists alleviate perioperative neurocognitive disorders by inhibiting microglia activation through the PI3K/AKT/FoxO1 pathway in aged rats |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Microglia, the principal sentinel immune cells of the central nervous system (CNS), play an extensively vital role in neuroinflammation and perioperative neurocognitive disorders (PND). Histamine, a potent mediator of inflammation, can both promote and prevent microglia-related neuroinflammation by activating different histamine receptors. Rat microglia express four histamine receptors (H1R, H2R, H3R, and H4R), among which the histamine 1 and 4 receptors can promote microglia activation, whereas the role and cellular mechanism of the histamine 2 and 3 receptors have not been elucidated. Therefore, we evaluated the effects and potential cellular mechanisms of histamine 2/3 receptors in microglia-mediated inflammation and PND. Methods This study investigated the role of histamine 2/3 receptors in microglia-induced inflammation and PND both in vivo and in vitro. In the in vivo experiments, rats were injected with histamine 2/3 receptor agonists in the right lateral ventricle and were then subjected to exploratory laparotomy. In the in vitro experiments, primary microglia were pretreated with histamine 2/3 receptor agonists before stimulation with lipopolysaccharide (LPS). Cognitive function, microglia activation, proinflammatory cytokine production, NF-κb expression, M1/M2 phenotypes, cell migration, and Toll-like receptor-4 (TLR4) expression were assessed. Results In our study, the histamine 2/3 receptor agonists inhibited exploratory laparotomy- or LPS-induced cognitive decline, microglia activation, proinflammatory cytokine production, NF-κb expression, M1/M2 phenotype transformation, cell migration, and TLR4 expression through the PI3K/AKT/FoxO1 pathway. Conclusion Based on our findings, we conclude that histamine 2/3 receptors ameliorate PND by inhibiting microglia activation through the PI3K/AKT/FoxO1 pathway. Our results highlight histamine 2/3 receptors as potential therapeutic targets to treat neurological conditions associated with PND. | ||
| 650 | 4 | |a Microglia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Histamine receptors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Perioperative neurocognitive disorders |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inflammatory factors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a TLR4 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a FoxO1 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Sha, Huan-Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yi-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Bhuiyan, Piplu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Na-Na |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Yan-Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Hong-Quan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuroinflammation |d London : BioMed Central, 2004 |g 17(2020), 1 vom: 22. Juli |w (DE-627)SPR02908735X |w (DE-600)2156455-3 |x 1742-2094 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2020 |g number:1 |g day:22 |g month:07 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12974-020-01886-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2020 |e 1 |b 22 |c 07 | ||